Product
Adjuvant nivolumab
1 clinical trial
1 indication
Indication
Malignant Melanoma Stage IIIClinical trial
Multicenter Phase 3 Trial Comparing Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma - NADINAStatus: Active (not recruiting), Estimated PCD: 2024-01-12